Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035555
Status:
COMPLETED
Last Update Posted:
2014-01-13
First Post:
2002-05-03
Brief Title:
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase IIIII Open-Label Randomized Controlled Multiple-Dose Study of Efficacy and Safety of BMS-224818 Belatacept as Part of a Quadruple Drug Regimen in First Renal Transplant Recipients
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether treatment with Belatacept BMS-224818 is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safetytolerability profile better kidney function and blood pressure fewer lipid problems less diabetes mellitus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None